Experimental depression drug aims to help when standard meds fail

NCT ID NCT02153502

Completed Disease control Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests whether a new drug called AVP-786 can help people with major depressive disorder who have not gotten enough relief from standard antidepressants. Participants take AVP-786 or a placebo alongside their current antidepressant for 10 weeks. The main goal is to see if the drug reduces depression symptoms more than placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AVP-786 (deuterium-modified dextromethorphan hydrobromide and quinidine sulfate combination)
What this could lead to: If successful, this could offer a new option for people with depression that hasn't improved with standard treatments, potentially improving mood and daily function.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply to everyone. The drug may cause side effects or prove no better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, TREATMENT-RESISTANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

depressive disorder Depressive Disorder, Treatment-Resistant major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSIVE DISORDER, TREATMENT-RESISTANT

Contacts and locations

Show contact details

Locations

Study site

Birmingham, Alabama, 35213, United States
Study site

Birmingham, Alabama, 35294, United States
Study site

Bellflower, California, 90706, United States
Study site

Costa Mesa, California, 92626, United States
Study site

Garden Grove, California, 92845, United States
Study site

Lomita, California, 90717, United States
Study site

Oceanside, California, 92056, United States
Study site

Riverside, California, 92506, United States
Study site

Santa Ana, California, 92706, United States
Study site

Sherman Oaks, California, 91403, United States
Study site

Denver, Colorado, 80239, United States
Study site

Bradenton, Florida, 34201, United States
Study site

Jacksonville, Florida, 32256, United States
Study site

Miami, Florida, 33155, United States
Study site

Orange City, Florida, 32763, United States
Study site

Orlando, Florida, 32801, United States
Study site

Decatur, Georgia, 30030, United States
Study site

Hoffman Estates, Illinois, 60169, United States
Study site

Valparaiso, Indiana, 46383, United States
Study site

Baltimore, Maryland, 21285, United States
Study site

Glen Burnie, Maryland, 21061, United States
Study site

Boston, Massachusetts, 02131, United States
Study site

Brooklyn, New York, 11241, United States
Study site

New York, New York, 10003, United States
Study site

Staten Island, New York, 10312, United States
Study site

Garfield Heights, Ohio, 44125, United States
Study site

Oklahoma City, Oklahoma, 73103, United States
Study site

Oklahoma City, Oklahoma, 73112, United States
Study site

Tulsa, Oklahoma, 74101, United States
Study site

Philadelphia, Pennsylvania, 19104, United States
Study site

Philadelphia, Pennsylvania, 19139, United States
Study site

Murray, Utah, 84123, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.